#None #San Diego #Oncolytics Biotech #pelareorep #Gastrointestinal Cancer

Oncolytics Biotech Hosts Key Opinion Leader Webinar on Cancer Treatments

On July 22, 2025, Oncolytics Biotech® Inc., a prominent player in the field of immunotherapy for oncology, will organize a significant webinar focused on the use of their investigational treatment, pelareorep, for metastatic pancreatic ductal adenocarcinoma (mPDAC) and other gastrointestinal cancers. This session will present insights from leading experts in the field of oncology and provides valuable updates on ongoing research and clinical applications.

Webinar Details

The interactive webinar will begin at 1:00 PM ET and will feature key opinion leaders (KOLs) specializing in gastrointestinal cancers, including:

• - Dr. Dirk Arnold - Director of Asklepios Tumorzentrum Hamburg
• - Dr. Alexander Eggermont - Professor at University Medical Center Utrecht
• - Dr. Sanjay Goel - Professor of Medicine at Rutgers Cancer Institute of New Jersey
• - Dr. Devalingam Mahalingam - Faculty at Northwestern University

These experts will engage in a comprehensive discussion surrounding the clinical data for pelareorep along with its potential as an immunotherapeutic strategy. This dialogue is particularly relevant as it centers on enhancing the therapeutic landscape for patients suffering from difficult-to-treat cancers.

Focus on Pelareorep

Pelareorep is an intravenously administered immunotherapeutic agent developed by Oncolytics Biotech. The treatment has shown promise in previous studies, demonstrating the ability to evoke anti-cancer immune responses. It not only promotes a favorable tumor environment but also has the capacity to convert “cold” tumors into “hot” ones, thereby improving the efficacy of immune responses. Significant advances have been recorded in its application within the realms of metastatic breast cancer and pancreatic cancer, making pelareorep a potential game-changer for those affected by these malignancies.

Furthermore, the ongoing development of pelareorep has reached critical milestones, with two randomized Phase 2 studies indicating encouraging outcomes. The company is also exploring combinations of pelareorep with other approved cancer treatments, thus aiming to provide comprehensive treatment options tailored to individual patient needs.

Expert Contributions

The KOLs featured in the webinar bring extensive experience and research credentials to the discussion:

• - Dr. Dirk Arnold, renowned for his leadership in various European oncological institutions, will share insights from the GOBLET trial, focusing on gastrointestinal cancers and drug development.
• - Dr. Alexander Eggermont has a prolific publication history, with over 900 peer-reviewed articles, and is known for his extensive work in immunotherapy, earning numerous accolades for his contributions to cancer research.
• - Dr. Sanjay Goel’s expertise lies in colorectal cancer and drug development, having been recognized for advancing research on health disparities in cancer treatment.
• - Dr. Devalingam Mahalingam is known for his clinical research in gastrointestinal cancers, having overseen numerous clinical trials, thus contributing to the fundamental understanding of cancer therapies.

Expectations from the Webinar

Attendees can anticipate a live question and answer segment following the formal presentation. This interactive format encourages engagement and allows participants to seek clarifications and deep insights directly from the experts.

How to Register

Interested individuals can register for the webinar on the Oncolytics Biotech official website. This event promises to be an essential platform for sharing knowledge, dissecting ongoing research, and discussing the future trajectory of immunotherapy in similar cancer types.

About Oncolytics Biotech Inc.

Oncolytics Biotech is at the forefront of clinical-stage biotechnology, tirelessly working towards innovative treatments for cancer. Apart from pelareorep, the company is committed to exploring numerous avenues in cancer therapeutics. Their dedication to enhancing patient outcomes through advanced therapeutic strategies illustrates their pivotal role in the sector. For more information, visit www.oncolyticsbiotech.com or follow them on their social media channels.

Conclusion

This upcoming KOL webinar is not just a discussion but a significant step toward broadening the horizons of cancer treatment, with Oncolytics Biotech leading the charge. Join the experts on July 22 to delve deeper into the advancements of immunotherapy and the promising future it holds for patients battling pancreatic and gastrointestinal cancers.